{"symbol":"MRK","fiscalQuarter":"Q1-2026","reportDate":"2026-04-30","reportTime":"BMO","status":"reported","company":{"name":"Merck & Co., Inc.","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/MRK/earnings/Q1-2026","estimates":{"consensusEps":-1.4733,"consensusRevenue":15843.94,"epsLow":-1.81,"epsHigh":-0.83,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Merck & Co., Inc. is a major player in the pharmaceuticals sector, focusing on innovative medicines and vaccines. With a market cap of $272 billion, the company is significant in the healthcare industry, particularly in areas like oncology and infectious diseases.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of a company's profitability and is closely watched by investors.","consensus":"-1.47"},{"name":"Revenue","why":"Revenue figures provide insight into the company's sales performance and market demand for its products.","consensus":"15.8B"}],"lastQuarterRecap":{"summary":"In the last quarter, Merck reported an EPS of $2.04, slightly beating expectations. The stock reacted positively, gaining 2.18% the next day.","promises":[]},"wallStreetExpectations":{"summary":"Analysts are expecting a challenging quarter for Merck, with a consensus EPS of -1.47, indicating potential losses. Revenue expectations are set at $15.8 billion, reflecting cautious optimism.","bullCase":"If Merck can exceed EPS expectations and show strong revenue growth, it could signal robust demand for its products, leading to a positive stock reaction.","bearCase":"Conversely, if the company reports a larger loss than anticipated or revenue falls short, it could raise concerns about its market position and future growth."},"optionsSignal":{"impliedMove":"4.8%","context":"The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q4-2025","epsSurprise":"+0.59%","reaction":"+2.18%"},{"quarter":"Q3-2025","epsSurprise":"+9.32%","reaction":"-0.35%"},{"quarter":"Q2-2025","epsSurprise":"+4.67%","reaction":"-1.70%"},{"quarter":"Q1-2025","epsSurprise":"+3.06%","reaction":"+1.40%"}],"pivotalQuestions":[{"question":"Will Merck's EPS come in better than the consensus estimate of -1.47?","whyItMatters":"This figure will be crucial in assessing the company's profitability and market confidence."},{"question":"How does Merck's revenue of $15.8 billion compare to expectations?","whyItMatters":"Revenue performance will indicate demand for Merck's products and overall business health."}],"thesisBreakLevels":{"bullTrigger":"An EPS of -1.20 or better would confirm the bull case.","bearTrigger":"An EPS worse than -1.70 would confirm the bear case.","context":"The market is debating whether Merck can maintain profitability amidst competitive pressures and market dynamics."},"scenarioPlaybook":{"beatAndRaise":"If Merck beats EPS expectations, history suggests the stock could rise around 2.1% based on past performance.","inLineCautious":"If results are in line with expectations, the stock may see muted movement as investors await further guidance.","miss":"A miss could lead to a decline, with historical patterns indicating a potential drop around 2.1%."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating Merck's ability to recover from recent challenges, particularly in oncology sales.","supportingPoints":["Merck has consistently beaten EPS estimates in the past, suggesting potential for a surprise.","The options market is pricing a larger move than historical averages, indicating investor uncertainty.","Recent insider buying may suggest confidence in the company's recovery."],"riskToConsensus":"If Merck's oncology sales show unexpected strength, it could significantly alter the earnings outlook."},"whatToListenFor":["Any updates on the performance of Merck's oncology products.","Management's commentary on market conditions and competitive pressures.","Details on cost management strategies and their impact on profitability.","Insights into future product pipeline developments and their expected contributions."],"metaDescription":"Merck (MRK) reports Q1 2026 earnings April 30. Analysts expect -$1.47 EPS on $15.8B revenue. Here's what to watch."},"postBrief":{"headline":"Merck Beats on EPS, Stock Down 1.6%","keyNumbers":[{"metric":"EPS","actual":"$-1.28","expected":"$-1.47","surprise":"+15.46%"},{"metric":"Revenue","actual":"N/A","expected":"$15.8B","surprise":"N/A"}],"managementCommentary":{"tone":"Unknown","keyQuotes":[],"summary":"No transcript is on record, and the analysis is based solely on numerical results."},"guidanceChanges":{"summary":"No guidance data is available.","changes":[]},"whatItMeans":"Merck's earnings report showed a better-than-expected EPS result, which was a positive surprise for investors. However, the stock still declined by 1.6% on the day, indicating that the market may have had concerns about other aspects of the company's performance or future outlook. The lack of revenue data and guidance may have contributed to the stock's negative reaction.","metaDescription":"Merck & Co. (MRK) Q1 2026 earnings: EPS beat by 15.46%. Stock down 1.6%. Full breakdown."}}